Potassium orotate, tablets 500 mg 20 pcs

Pharmacotherapeutic group: metabolic agent. ATX code: A05BA The drug is potassium salt of orotic acid. Orotic acid is one of the precursors of pyrimidine nucleotides that are part of nucleic acids involved in the synthesis of protein molecules, so orotic acid salts are considered as substances of anabolic action and are used in disorders of protein metabolism for their stimulation.

Potassium orotate stimulates the synthesis of nucleic acids, albumin production in the liver, especially in conditions of prolonged hypoxia (oxygen deficiency), increases appetite, has diuretic (diuretic) and regenerating properties.

Pharmacokinetics
After oral administration 10 % of the ingested dose is absorbed in gastrointestinal tract. It is converted into orotidine-5-phosphate in the liver. It is excreted by the kidneys (30% as metabolites).

Indications

In complex therapy as an adjuvant: for diseases of the liver and biliary tract caused by acute and chronic intoxications (with the exception of organic lesions of the liver and biliary tract);
with the consequences of malnutrition in children (nutritional and nutritional-infectious malnutrition);
during the period of recovery after illnesses;
with chronic physical overstrain.

Pharmacological effect

Pharmacotherapeutic group: metabolic agent. ATC code: A05BA The drug is a potassium salt of orotic acid. Orotic acid is one of the precursors of pyrimidine nucleotides that are part of nucleic acids that are involved in the synthesis of protein molecules, and therefore salts of orotic acid are considered as anabolic substances and are used for protein metabolism disorders to stimulate them.

Potassium orotate stimulates the synthesis of nucleic acids, albumin production in the liver, especially under conditions of prolonged hypoxia (lack of oxygen), increases appetite, has diuretic (diuretic) and regenerative properties.

Pharmacokinetics
After oral administration, 10% of the ingested dose is absorbed (absorbed) in the gastrointestinal tract. Converts to orotidine 5-phosphate in the liver. Excreted by the kidneys (30% in the form of metabolites).

Special instructions

During the treatment period, it is advisable to follow a diet.

The ability to influence the speed of reactions when driving vehicles or working with other mechanisms
The drug does not cause drowsiness or reduce the speed of psychomotor reactions.

Active ingredient

Orotic acid

Composition

Active ingredient:
Potassium orotate. –500.0 mg
Excipients:
lactose monohydrate – 165.0 mg
potato starch – 55.0 mg
povidone K-17. – 22.5 mg
calcium stearate – 7.5 mg

Contraindications

Hypersensitivity to the components of the drug; acute and chronic organic liver damage (including cirrhosis of the liver); ascites (accumulation of fluid in the abdominal cavity); urolithiasis; renal failure; children under 3 years of age.

Side Effects

Potassium orotate is generally well tolerated.

Interaction

Astringents and coating agents may slightly reduce the absorption of potassium orotate in the gastrointestinal tract.

Overdose

There are no data on overdose.

Storage conditions

In a dry place at a temperature not exceeding 25 ° C in the manufacturer’s packaging.
Keep out of the reach of children.

Shelf life

4 years.
After the expiration date indicated on the package, do not use.

Manufacturer

Update of PFC JSC, Russia